1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021

OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021

  • March 2015
  • 255 pages
  • ID: 2979101
In this report:
IN THE US, GLOBALDATA PROJECTS THE SEPSIS MARKET TO BE VALUED AT $##.##M IN 2016, WITH THE UPTAKE OF AKP-A'S ART-## ACCOUNTING FOR ##% OF TOTAL SALES IN THE FIRST YEAR OF THE FORECAST PERIOD SINCE IT IS EXPECTED TO BE THE FIRST PRODUCT TO REACH THE MARKET.
THE OVERALL ##MM SEPSIS MARKET IS EXPECTED TO INCREASE FROM $##.##M IN 2016 TO $##.##M IN 2021, AT A POSITIVE CAGR OF ##.##%.

Summary

Table of Contents

Search Inside

OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021

Brief

Sepsis patients suffer from a series of different complications arising from the presence of pathogens and/or their toxins in the blood or tissues, which cause a quickly progressing hyperactive host immune response and cellular dysfunction leading to mortality rates near 50.0 percent depending on disease severity. The syndrome places a main burden on the national healthcare systems of the overall marketplace, which for the purposes of this report is comprised of the U.S., France (FR), Germany (DE), Italy (IT), Spain (ES), and the UK. There are currently no marketed drugs to treat sepsis and current treatment options are limited to careful monitoring, pathogen-targeting therapies, and supportive care and symptom management.

For the purposes of this report, GlobalData defines the sepsis market to include sales of sepsis-specific, host-directed products in patients 18 years and older. Therefore a exhaustive analysis and sales projections for antibiotics is beyond the

Scope

of this business report. The projection of annual sales for medical devices is also beyond the

Scope

of this industry report, however anticipated launch dates and patient uptake estimates for these products is included in the forecast. GlobalData expects the sector to experience modest growth that is primarily driven by the increased uptake of novel therapies - led by Asahi Kasei Pharma America Corporation's ART-123 - in select patients as the critical care community regains confidence in sepsis-specific products and as more data is generated on their global efficacy and safety. Primary research revealed that skepticism, cynicism, and cautious optimism towards sepsis pipeline products is related to new high profile failures of products in clinical development.

Features

Key Questions Answered

- Established on interviews with leading opinion leaders, GlobalData has identified the main unmet needs in the sepsis marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2016-2021)?

- What research and development strategies will companies leverage to compete in the future sepsis marketplace?

- Which patient population are most likely to be targeted for sepsis-specific product development?

- What clinical and commercial factors are likely to influence sepsis product uptake in the U.S. and 5EU (France (FR), Germany (DE), Italy (IT), Spain (ES), and the United Kingdom (UK))?

Main results

- GlobalData projects the sepsis market in the U.S. and 5EU to grow from approximately $26m in 2016 to $354m in 2021, at a CAGR of 69%. This solid growth will be driven by the increased uptake of novel therapies - led by AKP's anticoagulant ART-123 - in select patients as the critical care community regains confidence in sepsis-specific products and more data is generated on their global efficacy and safety.

- KOLs interviewed by GlobalData were cautiously optimistic regarding the clinical benefits of pipeline products in their currently selected trial participants and reiterated farther improvements are essential in an area with main unmet medical needs.

- GlobalData anticipates that firms will increasingly turn to innovative R&D strategies, in unique the exploration of alternative approaches to clinical trial design and improved patient targeting - including adaptive design trials and companion diagnostics - in order to increase developmental efficiency, minimize upfront risk, and gain a ambitious advantage over rivals.

Overview

- Overview of sepsis, severe sepsis, and septic shock, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.

- Topline sepsis market revenue from 2016-2021. Annual cost of therapy and main pipeline product sales in this forecast period are included*.

- Key topics covered include tactical competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the sepsis market.

- Pipeline analysis: exhaustive data split across distinct phases, emerging novel trends under development, synopses of innovative early-stage projects, and in-depth analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

- Analysis of the current and future market competition in the overall sepsis market. Insightful review of the top industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Great reasons to purchasey

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most strong pipeline.

- Develop strategic management by understanding the trends shaping and driving the overall sepsis market.

- Drive revenues by understanding the main trends, innovative products and technologies, market segments, and firms likely to impact the sepsis market in the outlook.

- Specified effective sales and marketing strategies by understanding the challenging landscape and by analyzing the performance of different competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a ambitious advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and tactical partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Sepsis Diagnostics Market 2017-2021

Sepsis Diagnostics Sector: Worldwide Forecast until 2021

  • $ 3500
  • Industry report
  • October 2017
  • by Infiniti Research Limited

About Sepsis DiagnosticsSepsis is a three-staged syndrome; it starts with systemic infections leading to severe sepsis and ultimately causing sepsis shock, which is regarded as a medical emergency. Population ...

Ischemic Stroke Global Clinical Trials Review, H2, 2017

Clinical Research in Ischemic Stroke in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Ischemic Stroke Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Ischemic Stroke Global Clinical Trials Review, H2, 2017" provides an overview of Ischemic Stroke clinical ...

Hypotension Global Clinical Trials Review, H2, 2017

Clinical Research in Hypotension in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Hypotension Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Hypotension Global Clinical Trials Review, H2, 2017" provides an overview of Hypotension clinical trials ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.